NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

Five noteworthy health news stories – ED ads on prime time, expensive CA drugs & more

Posted By


On MSNBC, “Erectile dysfunction drug ads too hot for prime time?

An AP story, “$93,000 cancer drug: How much is a life worth?

Guy Boulton of the Milwaukee Journal-Sentinel on “Research could be key to lower health spending: Comparative-effectiveness studies can reduce spending on treatments that are ineffective or no more effective than less expensive alternatives.”

A Kaiser Health News piece, “Americans Still Confused, Divided About Health Law,” about a Kaiser Family Foundation poll that shows that “Misperceptions about the law also persist: for example, three in ten seniors believe the law will permit government panels to make decisions about end-of-life care for Medicare recipients (often referred to as “death panels”).”

And another Kaiser Health News piece, “As They Consolidate, Hospitals Get Pricier,” that shows how hospitals are “getting a boost from the health care reform law” but how “some observers and regulators also say it could hand hospitals more power to demand higher rates from insurers and employers.”

You might also like


Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.